公开(公告)号：EP1828209A2

公开(公告)日：2007-09-05

申请号：EP05826661.0

申请日：2005-12-19

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： KETTSCHAU, Georg ,  BRIEM, Hans ,  HARTUNG, Ingo ,  LUECKING, Ulrich ,  SCHAEFER, Martina ,  THIERAUCH, Karl-Heinz ,  SCHWEDE, Wolfgang ,  HUSEMANN, Manfred

IPC分类号： C07D513/08 ,  A61K31/529 ,  A61P35/00

CPC分类号： C07D513/08

摘要： The invention relates to sulfonamido-macrocycles according to the general Formula (I) and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling. (I), wherein R1, R2, R4, A, X, Y, Z and m have the meaning as given in the specification and the claims.

摘要翻译： 本发明涉及根据通式（I）的亚磺酰氨基大环及其盐，涉及包含磺酰氨基大环的药物组合物，以及制备磺酰氨基大环的方法以及其用于制备用于 治疗血管生长失调的疾病或伴随血管生长失调的疾病，其中所述化合物有效地干扰血管生成素并因此影响Tie2信号传导。 （I）的化合物，其中R1，R2，R4，A，X，Y，Z和m具有说明书和权利要求书中给出的含义。

公开(公告)号：EP2176266A2

公开(公告)日：2010-04-21

申请号：EP06775928.2

申请日：2006-09-01

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： PRIEN, Olaf ,  BADER, Benjamin ,  ZÜGEL, Ulrich ,  INCE, Stuart James ,  HUWE, Christoph ,  SCHUCK, Karina ,  EIS, Knut ,  LÜCKING, Ulrich ,  JAUTELAT, Rolf ,  GÜNTHER, Judith ,  HUSEMANN, Manfred

IPC分类号： C07D487/04 ,  A61K31/425 ,  A61P29/00

CPC分类号： C07D487/04

摘要： The invention relates to novel inhibitors for kinases, methods for producing such inhibitors, intermediate products for producing the same, and uses thereof.

公开(公告)号：EP2049539A1

公开(公告)日：2009-04-22

申请号：EP07726170.9

申请日：2007-06-20

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： INCE, Stuart ,  PRIEN, Olaf ,  LU, Shoufu ,  YU, Hongyi ,  HUSEMANN, Manfred ,  SCHUCK, Karina

IPC分类号： C07D487/04 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D487/04

摘要： The invention relates to pyrazolopyrimidines according to the general formula (I) : and salts thereof, to pharmaceutical compositions comprising said pyrazolopyrimidines and to a method of preparing said pyrazolopyrimidines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment or prophylaxis of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth

公开(公告)号：EP1879900A2

公开(公告)日：2008-01-23

申请号：EP06742601.5

申请日：2006-04-10

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： LÜCKING, Ulrich ,  KETTSCHAU, Georg ,  BRIEM, Hans ,  SCHWEDE, Wolfgang ,  SCHÄFER, Martina ,  THIERAUCH, Karl-Heinz ,  HUSEMANN, Manfred

IPC分类号： C07D513/08 ,  C07D239/04 ,  A61K31/529 ,  C07C317/12

CPC分类号： C07D209/48 ,  C07D239/42 ,  C07D513/08

摘要： The invention relates to macrocyclic sulfoximines of the general Formula I : (I), wherein A, X, Y, R1, R2 and R3 have the meaning as given in the specification and the claims, and to salts thereof; to pharmaceutical compositions comprising the macrocyclic sulfoximines, and to a method of preparing the macrocyclic sulfoximines, as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

公开(公告)号：EP1844056A2

公开(公告)日：2007-10-17

申请号：EP05820679.8

申请日：2005-12-19

申请人： Bayer Schering Pharma Aktiengesellschaft

发明人： KETTSCHAU, Georg ,  BRIEM, Hans ,  LUECKING, Ulrich ,  SCHAEFER, Martina ,  THIERAUCH, Karl-heinz ,  SCHWEDE, Wolfgang ,  HUSEMANN, Manfred ,  HUTH, Andreas

IPC分类号： C07D513/08

CPC分类号： C07D513/08

摘要： The invention relates to sulfonamido-macrocycles according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the sulfonamido-macrocycles and to a method of preparing the sulfonamido-macrocycles as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling. (I), wherein R1, R2 and R3 have the meaning as given in the specification and the claims.